OWCP: A Unique Pure-Play in the Epicenter of Cannabis Research (with Executive Interview)
February 28th, 2017
News, Top News
Israel has become the global epicenter for cannabis research and development over the past several decades. Teva Pharmaceuticals Inc.’s (NASDAQ: TEVA) purchase of Syqe Medical and the government’s moves to open up medical cannabis exports only underscore the country’s commitment to bringing cannabis therapeutics to the rest of the world. As a result, investors looking for opportunities in cannabis biotechs should definitely be looking at Israel.
In this article, we will take a look at OWC Pharmaceuticals Inc. (OTCQB: OWCP) and why it represents a compelling pure-play in Israel’s burgeoning cannabis sector.
Epicenter of Cannabis R&D
Israel has always been on the cutting-edge of cannabis research and development. In fact, Israeli organic chemist Professor Raphael Mechoulam and his team of scientists originally discovered the chemical structure of cannabidiol (CBD) and were the first to isolate tetrahydrocannabinol (THC). The United States fell significantly behind when President Nixon determined that cannabis was a Schedule I Controlled Substance in the 1970s – a move that prevented research for decades.
Since then, Israel has continued to be a pioneer of the cannabis industry. The government recently moved to decriminalize the drug for personal use while approving a plan that would enable medical marijuana companies to export products internationally. These moves prompted investors to invest some $100 million into over 70 companies involved in the industry alongside the government’s own $2 million investment designed to spur the development of new strains.
The country’s largest pharmaceutical companies have also embraced cannabis rather than avoiding it. For instance, Teva – the largest producer of generic pharmaceuticals in the world – recently purchased Syqe Medical, which has developed an innovative medical cannabis inhaler. The move signals an entirely different approach to the market than large U.S. giants like Pfizer Inc. (NYSE: PFE).
Teva Pharmaceuticals Inc. may be involved in the cannabis industry, but it’s hardly a pure-play given its extensive reach into all areas of the pharmaceutical industry. Investors may want to take a look at pure-play opportunities like OWC Pharmaceuticals instead, given that 100% of the company’s focus is dedicated to cannabinoid research and development and it could stand to benefit the most in terms of percentage revenue and market cap gains.
OWC Pharmaceuticals owns 100% of One World Cannabis Ltd., which was formed to apply pharmaceutical research protocols and disciplines to the global medical cannabis space. Dr. Yehuda Baruch spearheads the company’s research efforts after serving as the head of the Israeli Ministry of Health’s Medical Cannabis Program over 10 years, overseeing clinical trials, regulatory compliance, and other industry-wide issues.
The rest of the company’s management team is experienced in areas of business development, international sales, public accounting, and investment banking. For a company of its size, the management team is both impressive and highly-capable of executing on its mission of bringing Israeli cannabis science to U.S. state-licensed businesses, Europe, Canada, South America, and other end markets where medical cannabis has been legalized.
Broad Potential with Catalysts
OWC Pharmaceuticals is focused on the development of two delivery systems: A proprietary, cannabinoid-enriched sublingual tablet and a proprietary topical compound. Between these, the company plans to address several multi-billion dollar end markets including serious medical conditions like multiple myeloma, post-traumatic stress disorder, fibromyalgia, and psoriasis, along with hundreds of additional addressable indications down the road.
Orally disintegrating tablets
OWC Pharmaceuticals announced the development of a proprietary, cannabinoid-enriched sublingual tablet for the administration of medical cannabis in October of 2016. The tablet was developed to increase the bioavailability of cannabinoids and provide an optimal administration method for consistent dosing. The company plans to develop the tablet to treat conditions like multiple myeloma, post-traumatic stress disorder, and fibromyalgia.
Prior to launching the tablet, the company completed in-vitro testing of a cannabinoid-based formulation for multiple myeloma in March of 2016. Management plans to proceed with pre-clinical trials approved by the Institutional Review Board (IRB) to duplicate those results in mice before proceeding with human trials. The in-vitro testing, however, showed 100% malignant cell death in 60% of infected mice cells – promising results.
OWC Pharmaceuticals formulated a topical cannabinoid-based cream for the treatment of psoriasis in partnership with one of Israel’s largest cosmetic manufacturers – Emilia Cosmetics Ltd. – in March of 2016. Soon after, the company completed the Institutional Review Board (IRB) protocol for a Phase I equivalent, double-blind, randomized and placebo-controlled study and secured $300,000 in funding from U.S.-based Medmar LLC.
The company began the trial in conjunction with a major Israel-based medical center in December of 2016 to evaluate the safety and efficacy of the topical cream. Management is hopeful that the psoriasis cream will be launched in the U.S. and European markets during the second quarter of this year depending on state-to-state regulatory approvals.
OWC Pharmaceuticals Inc. (OTCQB: OWCP) represents a unique pure-play in Israel’s burgeoning cannabis industry. With an experienced management team at the helm, the company has focused its efforts on treating serious medical conditions with two core delivery systems that include a sublingual tablet that enhances bioavailability and a topical cream. Investors may want to keep an eye on the stock given these near-term catalysts in Q2’2017.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.